Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1Lymphoid 1Head & Neck 1Genitourinary 1CNS 1Breast 1

Conditions

Myelodysplastic Syndromes 3Leukemia, Myeloid, Acute 3Primary Myelofibrosis 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasm Metastasis 2Myeloproliferative Disorders 2Multiple Myeloma 2Leukemia, Myelomonocytic, Chronic 2Breast Neoplasms 2Urologic Neoplasms 1Thyroid Neoplasms 1Thrombocytosis 1Soft Tissue Neoplasms 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Polycythemia Vera 1Pharyngeal Neoplasms 1Pancreatic Neoplasms 1Neurofibromatosis 2 1Neoplasms, Mesothelial 1Neoplasms 1Myelodysplastic-Myeloproliferative Diseases 1Mycosis Fungoides 1Mouth Neoplasms 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell 1

Interventions

temsirolimus 1Valproic Acid 1Sirolimus 1Immunoglobulin G 1Disulfides 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphangioleiomyomatosis × Immunoglobulin G × Myeloid × Clear all
NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡